Company News

miRagen Therapeutics Publishes Data Demonstrating that Therapeutic Dosing of miR-15 Family Inhibitor Protects Against Ischemic Injury to the Heart

miRagen Therapeutics Publishes Data Demonstrating that Therapeutic Dosing of miR-15 Family Inhibitor Protects Against Ischemic Injury to the Heart

miRagenMyocardial infarction (MI) is a leading cause of death worldwide. Because endogenous cardiac repair mechanisms are not sufficient for meaningful tissue regeneration, MI results in loss of cardiac tissue and detrimental remodeling events. MicroRNAs (miRNAs) are small, noncoding RNAs that regulate gene expression in a sequence dependent manner.

Researchers at miRagen Therapeutics set out to examine whether miRNAs are involved in ischemia-reperfusion injury of the porcine heart. They used LC Sciences’ miRNA microarray service to perform analysis on porcine cardiac samples after ischemia-reperfusion injury and profiled miRNA expression in the infarct and border zone regions post-MI compared with control tissue from sham-operated animals. The data showed a distinct miRNA expression signature and indicated that miRNAs are dynamically regulated in different regions of the porcine heart during post-MI remodeling, which could be confirmed by miRNA-specific real-time PCR analysis.

(read the press release… )

www.miragentherapeutics.com

Hullinger TG, Montgomery RL, Seto AG, Dickinson BA, Semus HM, Lynch JM, Dalby CM, Robinson K, Stack C, Latimer PA, Hare JM, Olson EN, van Rooij E. (2011) Inhibition of miR-15 Protects Against Cardiac Ischemic Injury. Circ Res [Epub ahead of print]. [abstract]